- AFP 4
- Start Date
- Expiration Date
- PRENATAL RISK QUADRUPLE MKR, Prenatal Risk Assessment, Quadruple Marker
- CPT Codes
- 81511; codes are different if you DIRECTLY bill Medicare
- Reference Test
- ATLAS Test Code
- Transport Info
- Fasting Required?
- Patient Instructions
Specimen must be collected between 15th and 22nd week of gestation for a complete risk analysis (optimal time is 16-18 weeks) Collect sample prior to amniocentesis Complete a Prenatal Risk Information Sheet and send with sample (requires following items of information): – Estimated due date by LMP – Mother’s weight in pounds – Mother’s status of insulin-dependent diabetes – # of fetuses in current pregnancy (1 or 2) Note: Pregnancies with more than 2 fetuses cannot be assessed – Mother’s race – Mother’s exact date of birth (mm/dd/yyyy) – Is this a repeat sample? (yes/no)
- Reference Range
Quantitative Chemiluminescent Immunoassay (CLIA)
Used to screen for fetal risk of open Neural Tube Defects (NTD), Down Syndrome (DS) and Trisomy 18 This procedure includes performing four (4) tests, alpha-fetoprotein (AFP), human chorionic gonadotropin (hCG), unconjugated/free estriol (uE3) and Inhibin-A, on serum specimens from expectant mothers at the gestational age between 15 and 22 weeks. Based on the results of these tests and maternal age at the expected date of delivery (EDD), risk factors for bearing a child with open Neural Tube Defects (NTD), Down Syndrome (DS), and/or Trisomy 18 are calculated.